| Trial ID: | L2484 |
| Source ID: | NCT03563794
|
| Associated Drug: |
Csii+Vildagliptin
|
| Title: |
Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
T2DM
|
| Interventions: |
DRUG: CSII+Vildagliptin|DRUG: CSII(insulin Lispro)
|
| Outcome Measures: |
Primary: blood glucose, changes from baseline in FPG and 2hPBG, 7 days | Secondary: hypoglycemia, frequancy of hypoglycemia, 7 days
|
| Sponsor/Collaborators: |
Sponsor: The First Affiliated Hospital of Xiamen University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
400
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2018-06-10
|
| Completion Date: |
2019-12-10
|
| Results First Posted: |
|
| Last Update Posted: |
2018-06-20
|
| Locations: |
The first afilliated hospital of Xiamen university, Xiamen, Fujian, 361003, China
|
| URL: |
https://clinicaltrials.gov/show/NCT03563794
|
